ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 543
Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
9:00AM-11:00AM
Abstract Number: 499
Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib
9:00AM-11:00AM
Abstract Number: 533
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
9:00AM-11:00AM
Abstract Number: 510
Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies
9:00AM-11:00AM
Abstract Number: 540
Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
9:00AM-11:00AM
Abstract Number: 503
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 514
BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
9:00AM-11:00AM
Abstract Number: 527
Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study
9:00AM-11:00AM
Abstract Number: 520
Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach
9:00AM-11:00AM
Abstract Number: 531
Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials
9:00AM-11:00AM
Abstract Number: 526
Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition
9:00AM-11:00AM
Abstract Number: 551
Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-
9:00AM-11:00AM
Abstract Number: 539
Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis
9:00AM-11:00AM
Abstract Number: 546
Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 541
Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries
9:00AM-11:00AM
Abstract Number: 535
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies
9:00AM-11:00AM
Abstract Number: 534
Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study
9:00AM-11:00AM
Abstract Number: 536
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
9:00AM-11:00AM
Abstract Number: 530
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
9:00AM-11:00AM
Abstract Number: 516
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards
9:00AM-11:00AM
Abstract Number: 495
Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates
9:00AM-11:00AM
Abstract Number: 512
Efficacy Response to Baricitinib Based on Baseline Characteristics in Patients Who Are Inadequate Responders to Conventional DMARD
9:00AM-11:00AM
Abstract Number: 525
Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center
9:00AM-11:00AM
Abstract Number: 517
Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 505
Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy
9:00AM-11:00AM
Abstract Number: 519
Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
9:00AM-11:00AM
Abstract Number: 532
Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 528
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
9:00AM-11:00AM
Abstract Number: 508
Improved Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Failed Adalimumab or Placebo Treatment and Were Rescued with Baricitinib
9:00AM-11:00AM
Abstract Number: 545
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
9:00AM-11:00AM
Abstract Number: 549
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 542
Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?
9:00AM-11:00AM
Abstract Number: 548
LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 515
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
9:00AM-11:00AM
Abstract Number: 547
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 509
Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
9:00AM-11:00AM
Abstract Number: 550
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
9:00AM-11:00AM
Abstract Number: 500
Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
9:00AM-11:00AM
Abstract Number: 504
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 537
No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies
9:00AM-11:00AM
Abstract Number: 501
Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
9:00AM-11:00AM
Abstract Number: 524
Predictors of Mortality in RA Patients before Biologic Therapy
9:00AM-11:00AM
Abstract Number: 523
Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies
9:00AM-11:00AM
Abstract Number: 529
Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience
9:00AM-11:00AM
Abstract Number: 502
Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo
9:00AM-11:00AM
Abstract Number: 496
Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections
9:00AM-11:00AM
Abstract Number: 498
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
9:00AM-11:00AM
Abstract Number: 511
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
9:00AM-11:00AM
Abstract Number: 544
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
9:00AM-11:00AM
Abstract Number: 538
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 497
The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and Colon Inflammation in a Mouse Model of Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 518
The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 506
The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol
9:00AM-11:00AM
Abstract Number: 513
Time to Achieve Moderate/Low Disease Activity and Remission in RA Patients on Baricitinib Compared to Adalimumab, Methotrexate, and Placebo
9:00AM-11:00AM
Abstract Number: 507
Tofacitinib Monotherapy Improves Left Ventricular Mass and Cardiac Output in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 522
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
9:00AM-11:00AM
Abstract Number: 521
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology